Recently Paul Goldberg of The Cancer Letterreported on an investigation into Duke cancer researcher Anil Potti, M.D., and claims made that he was a Rhodes Scholar in Australia. The misrepresentation was made on grant applications to National Institutes of Health (NIH) and the American Cancer Society (ACS).
The Cancer Letter, a $375 per year go-to newsletter on cancer research, funding, and drug development, has made this issue free at this PDF link.
News & Observer higher education reporter Eric Ferreri has a nice overview of the situation. Potti has been placed on administrative leave by Duke, and the ACS has suspended payments on his grant and initiated their own investigation. Read more »
*This blog post was originally published at Terra Sigillata*
For the first time in history, a living organism has been manufactured with the help of a computer-generated genome. Dr. Jon LaPook reports on the groundbreaking discovery’s widespread implications.
Craig Venter and his team of scientists recently announced that they had created the first “synthetic cell” — a bacterium controlled by genetic material that they had designed on a computer and concocted from four bottles of chemicals. This is the closest thing to creating life that has happened outside of a science-fiction movie. If it doesn’t fire your imagination, then you should fire your imagination.
Basically, what Venter et al did was remove the “brain” (the genetic material that runs the cell) from one species of bacteria (Mycoplasma capricolum) and inserted a new brain — one synthetically created based very closely on the known genetic makeup of a second species of bacteria (Mycoplasma mycoides). The new organism then divided just as a normal cell would and followed the instructions of the new brain. Think micro-Avatar, except that the Avatar’s body morphs into one designed by its new brain. Read more »
I’ve been writing about personal genomics for years. The standard concept of it is that you can order such genetic tests online, send your saliva or buccal swab to the lab where they analyze your DNA, then you can check online what kind of diseases you have elevated or lowered risk for. That’s how Navigenics, 23andMe or Pathway Genomics works. Now Pathway had a major announcement:
San Diego based startup Pathway Genomics announced [May 18th] that it will begin selling its DNA collection kits at Walgreens drugstores beginning in mid-May, for about $20 to $30. Unlike a pregnancy test, users won’t be able to get results immediately. They will have to send in their saliva sample and then go to Pathway’s website to select the particular test they want. Users choose from drug response ($79), which assesses how well an individual can metabolize certain drugs, predicting the best dosage for that person or whether they will be susceptible to certain side effects; pre-pregnancy planning ($179), which determines whether parents carry mutations for serious genetic diseases; health conditions ($179), which assesses risk for a number of conditions, including diabetes, Alzheimer’s, prostate cancer and more; or a combination of all three ($249). The kits won’t be sold in New York because the state’s laws require medical professionals to be involved in this type of testing.
As you may know, I’m not totally against direct-to-consumer genetic testing, but I really would like to see doctors and genetic counselors in this process. I think selling such kits through drugstores can only happen in the U.S. right now. Read more »
*This blog post was originally published at ScienceRoll*
What’s amazing is that despite the vocal movement to empower patients, no one has put together a well-referenced, readable book to help patients understand how they should use personalized medicine to influence their health — until now.
Enter The Decision Tree: Taking Control of Your Health in the New Era of Personalized Medicine (Rodale 2010), something of a blueprint of patient liberation written by Thomas Goetz, executive editor of Wired magazine. It offers constructive narrative not only about the importance of the decisions we make but how to apply the concept of an old-fashioned decision tree in making those decisions. Read more »
*This blog post was originally published at 33 Charts*
As the costs of sequencing our DNA shrink and the roles of digital media in our lives expand, we will need to understand who (or what) controls the ownership, access and use of our genomic information.
From state regulation to Google to Facebook, who controls the acquisition, transmission and replication of our genomic information and material will become an important battle in the 21st century. Read more »
*This blog post was originally published at Phil Baumann*
It’s no secret that doctors are disappointed with the way that the U.S. healthcare system is evolving. Most feel helpless about improving their work conditions or solving technical problems in patient care. Fortunately one young medical student was undeterred by the mountain of disappointment carried by his senior clinician mentors…
I am proud to be a part of the American Resident Project an initiative that promotes the writing of medical students residents and new physicians as they explore ideas for transforming American health care delivery. I recently had the opportunity to interview three of the writing fellows about how to…
I m often asked to do book reviews on my blog and I rarely agree to them. This is because it takes me a long time to read a book and then if I don t enjoy it I figure the author would rather me remain silent than publish my…
When I was in medical school I read Samuel Shem s House Of God as a right of passage. At the time I found it to be a cynical yet eerily accurate portrayal of the underbelly of academic medicine. I gained comfort from its gallows humor and it made me…
I am hesitant to review diet books because they are so often a tangled mess of fact and fiction. Teasing out their truth from falsehood is about as exhausting as delousing a long-haired elementary school student. However after being approached by the authors’ PR agency with the promise of a…
